Loading...

KPTI KARYOPHARM THERAPEUTICS INC Earnings Reports 8-K Filing

KRYP

KPT

KARYOPHARM THERAPEUTICS INC

(KPTI)

2026 8-K

Securities Placement

Stock Purchase Agreement

Credit Agreement Update

Share Increase Approval

Financial Results Announced

Financial Update

Earnings Announcement

Financial Transactions

Financial Restructuring

Board Resignation

Potential Financing Transac...

Equity Offerings

Financial Statements

Financial Results

Executive Compensation

Shareholder Approvals

Management Change

Regulatory Update

Management Change

Lease Amendment

Financial Results

Clinical Trial Update

Nasdaq Compliance Notice

Annual Meeting Approval

Exchange of Convertible Sen...

Debt Restructuring, Convert...

Financial Results Announcement

Compliance Regained

Earnings Reports

Resignation of Director

Financial Results Announcement

Appointment of Independent ...

Annual Meeting Results

Financial Results Announcement

Regulation FD Disclosure

Equity Awards Approval

Earnings Report

External Links:

On January 12, 2026, Karyopharm Therapeutics Inc. reported estimated total revenues of $33 million for Q4 2025 and $145 million for the full year 2025, with net product revenue from U.S. XPOVIO at approximately $32 million for Q4 2025 and $115 million for the full year. The company expects to maintain sufficient liquidity of approximately $64 million to support its operations into Q2 2026.

AI Assistant

KARYOPHARM THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.